01 Dec Laminar Pharma announces that it will reach 1.2M euros with its latest round of financing

Posted at 18:18h in Press by
  • One week before closing the funding round, the company has surpassed 90% of the target figure.
  • The funding round is managed through the Fellow Funders Crowd Investment platform and is part of the preparations prior to Laminar joining BME Growth.
  • The company’s stock market debut on BME Growth (formerly Alternative Stock Market) is expected to take place in the first quarter of 2021.

Palma de Mallorca, November 19, 2020. Laminar Pharma, a biotech company based in the Balearic Islands, is getting closer and closer to its IPO. It launched a funding round this month to increase its investment in research staff and advance the development of clinical trials.

This operation aims to raise 1.2 million euros

The financing round was launched on October 30 with the aim of raising 1.2 million euros and is currently available on the Fellow Funders Crowd Investment platform. In the first two weeks, thanks to the trust of numerous investors, more than one million euros have been raised, which is equivalent to 92% of the target set. As there are still another two weeks left, everything suggests that the target will be met. In addition to this main source of financing, which is private investment, Laminar Pharma has received support from the Spanish government, Spain’s regional governments and the European Commission.

Pablo Escribá, CEO of the biopharmaceutical company, has a positive outlook: “We are optimistic about exceeding the planned target, as we did in the round at the end of last year. Currently at Laminar Pharma we hold patents for 8% of all drugs under development by Spanish biotechnology companies in our country, according to the pipeline of the Spanish Association of Bio-companies (ASEBIO) and we hope to grow in valuation as we advance in the clinical research stages of our drugs undergoing development. The company plans to request marketing authorization from regulatory agencies in two years, with the aim of announcing our first market launch in 2023.”

Fellow Funders partner Mariano Colmenar is satisfied with the operation, which is run by his own collective financing platform, authorized and supervised by the National Securities Market Commission (CNMV) since 2016. “We have shown that investors see a promising future in the biotechnology sector, anticipating good benefits. The pharmaceutical market is a long-term market, since years of research and clinical trials are necessary before the products can safely be launched to market.”

About Laminar Pharma
www.laminarpharma.com

The main activity of the company is in the research and development of chemotherapeutic treatments for neurological tumors, having licensed its own anti-tumor products for glioma, lung cancer and endometrial cancer. Another licensed product is in an advanced phase of study to alleviate neuropathic pain.

Laminar Pharma rationally designs its patented compounds, an extensive family of totally innovative drugs whose scientific basis is called Melitherapy or membrane lipid therapy (MLT). Currently, the company is studying the clinical effectiveness of several drugs designed under the MLT platform for the treatment of certain oncological pathologies. The most advanced product is the LAM561 molecule for chemotherapy treatment of glioblastoma, one of the most frequent and aggressive brain tumors. In addition, one aspect that has been valued positively by investors is Laminar’s commitment to waste management and its own recycling, an example of management with ESG, environmental, social and governance criteria.

About Fellow Funders:
www.fellowfunders.finance

Fellow Funders is an independent firm whose mission is to support SMEs and startups in their expansion and consolidation plans through the search of an optimal financing model. The Finance Symphony harmonizes the 4 movements at the service of entrepreneurs, managers and their companies, as well as investors: starting with the valuation of a company through Fair Value, through financing rounds via the Crowd Investment platform, financial and strategic advice through Alternative Assets, and finally accompanying its clients in their stock market launch with its Capital Markets division. Those four movements are synergistic and harmonic. They work together to generate the same melody, offering their clients the services they need for their transformation, corporate growth and internationalization.